These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 11207510)
1. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Poynard T; Regimbeau C; Benhamou Y Aliment Pharmacol Ther; 2001 Mar; 15(3):355-61. PubMed ID: 11207510 [TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Poynard T; Naveau S; Mory B; Chaput JC Aliment Pharmacol Ther; 1994 Oct; 8(5):499-510. PubMed ID: 7865642 [TBL] [Abstract][Full Text] [Related]
3. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Dobrilla G; Imbimbo BP; Piazzi L; Bensi G Gut; 1990 Mar; 31(3):355-8. PubMed ID: 2182401 [TBL] [Abstract][Full Text] [Related]
4. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Battaglia G; Morselli-Labate AM; Camarri E; Francavilla A; De Marco F; Mastropaolo G; Naccarato R Aliment Pharmacol Ther; 1998 Oct; 12(10):1003-10. PubMed ID: 9798806 [TBL] [Abstract][Full Text] [Related]
5. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. Van Outryve M; Mayeur S; Meeus MA; Rosillon D; Hendrickx B; Ceuppens M J Clin Pharm Ther; 1995 Oct; 20(5):277-82. PubMed ID: 8576295 [TBL] [Abstract][Full Text] [Related]
6. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Passaretti S; Guslandi M; Imbimbo BP; Daniotti S; Tittobello A Aliment Pharmacol Ther; 1989 Jun; 3(3):267-76. PubMed ID: 2520622 [TBL] [Abstract][Full Text] [Related]
7. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Centonze V; Imbimbo BP; Campanozzi F; Attolini E; Daniotti S; Albano O Am J Gastroenterol; 1988 Nov; 83(11):1262-6. PubMed ID: 3055943 [TBL] [Abstract][Full Text] [Related]
8. A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control. Defrance P; Casini A Ital J Gastroenterol; 1991 Nov; 23(8 Suppl 1):64-6. PubMed ID: 1756286 [TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome]. Wittmann T; Fehér A; Rosztóczy A; Jánosi J Orv Hetil; 1999 Feb; 140(9):469-73. PubMed ID: 10204402 [TBL] [Abstract][Full Text] [Related]
10. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597 [TBL] [Abstract][Full Text] [Related]
11. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. Ferrari A; Cavallero M; Spandre M; Gemme C; Rossini FP; Imbimbo BP Clin Ther; 1986; 8(3):320-8. PubMed ID: 3521859 [TBL] [Abstract][Full Text] [Related]
12. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Baldi F; Longanesi A; Blasi A; Monello S; Cestari R; Missale G; Corazziari E; Badiali G; Marzio L; Di Felice F Hepatogastroenterology; 1992 Oct; 39(5):392-5. PubMed ID: 1459516 [TBL] [Abstract][Full Text] [Related]
13. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Martínez-Vázquez MA; Vázquez-Elizondo G; González-González JA; Gutiérrez-Udave R; Maldonado-Garza HJ; Bosques-Padilla FJ Rev Gastroenterol Mex; 2012; 77(2):82-90. PubMed ID: 22672854 [TBL] [Abstract][Full Text] [Related]
14. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Lanfranchi GA; Bazzocchi G; Campieri M; Brignola C; Fois F; Imbimbo BP Eur J Clin Pharmacol; 1988; 33(6):571-5. PubMed ID: 3366160 [TBL] [Abstract][Full Text] [Related]
15. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Mitchell SA; Mee AS; Smith GD; Palmer KR; Chapman RW Aliment Pharmacol Ther; 2002 Jun; 16(6):1187-95. PubMed ID: 12030962 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. Darvish-Damavandi M; Nikfar S; Abdollahi M World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Jailwala J; Imperiale TF; Kroenke K Ann Intern Med; 2000 Jul; 133(2):136-47. PubMed ID: 10896640 [TBL] [Abstract][Full Text] [Related]
18. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Evangelista S Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053 [TBL] [Abstract][Full Text] [Related]
19. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Awad R; Dibildox M; Ortiz F Acta Gastroenterol Latinoam; 1995; 25(3):137-44. PubMed ID: 8600700 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the colonic motor response to eating by pinaverium bromide in irritable bowel syndrome patients. Fioramonti J; Frexinos J; Staumont G; Bueno L Fundam Clin Pharmacol; 1988; 2(1):19-27. PubMed ID: 3371838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]